Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy

Schlieren / Zurich, Switzerland, 27 August, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique human immune responses into superior medicines to treat viral infections and cancer, today announces that Alex Bastian has joined the Company as VP Commercial Strategy.

Alex Bastian is an experienced commercial leader in the biotech sector. Most recently he was VP Commercial & Patient Access at AM-Pharma, where he led market access for an innovative in-hospital therapy for acute kidney injury.

Prior to joining AM-Pharma, Alex was VP, Head of Value & Market Access at Galapagos where he led the creation of a global function for market access, health economics, and policy, built the team and launched a product in a competitive and dynamic therapy area. He previously held various senior roles in big pharma including at Incyte Consulting in both Europe and the US.

Erik van den Berg, CEO of MTx, commented: “Alex joins us at an exciting time as we progress towards initiating a Phase III trial in kidney transplant patients with BK virus infection ahead of commercial launch. We are delighted to bolster our in-house expertise with such a high calibre individual and on behalf of the senior leadership team I warmly welcome Alex to the company.”

Alex Bastian, VP Commercial Stratergy at MTx, added: “With a best and first-in-class antibody for BK viremia, MTx offers new hope for patients with no effective treatment options. I am excited to join a company with such a promising asset alongside a powerful technology platform and I look forward to working with the team.”

Alex is completing a Doctor of Public Health at the Johns Hopkins Bloomberg School of Public Health, US. He has an MBA from IESE Business School in Barcelona, Spain and a BA from the University of Minnesota, US.

In May, MTx announced that it had raised an additional CHF 20 million, bringing in new investors Ysios Capital and Kurma Partners and increasing its Series C financing to CHF 45 million. In July, the Company announced the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has as had an extensive executive career in the international biopharma space, including over 10 years of commercial experience working in the virology field at Gilead Sciences.